INTRODUCTION
Thyroid functional disorders are commonly observed in chronic kidney disease (CKD) patients [1 & ]. Primary hypothyroidism, which is typically identified by biochemical tests including an elevated serum thyrotropin (TSH) level in conjunction with a low or normal thyroxine (T4) level (defined as overt and subclinical hypothyroidism, respectively) [2] , is disproportionately more prevalent in patients with advanced kidney dysfunction compared to those with normal function [3] . In addition, various thyroid functional test abnormalities are frequently seen in CKD patients, resulting from alterations in thyroid hormone synthesis, metabolism, and regulation [1 & ,4]. Although early studies hypothesized that thyroid hormone deficiency may be a physiologic adaptation in kidney disease patients [5] , contemporary data have demonstrated that hypothyroidism is associated with higher risk of cardiovascular disease and death in this population [1 & , 6-8,9 & ]. In this review, we will examine potential mechanistic links between thyroid and kidney disease, describe common patterns of thyroid functional test alterations in CKD, summarize existing evidence of thyroid hormone deficiency as a risk factor for cardiovascular disease and death in CKD, including underlying pathophysiologic mechanisms, and discuss the clinical management of hypothyroidism in CKD patients and future areas of research.
HYPOTHYROIDISM: A COMMON YET UNDER-RECOGNIZED ENDOCRINE DISORDER IN KIDNEY DISEASE
Although a greater emphasis has been placed upon other endocrine disorders in CKD (e.g., secondary hyperparathyroidism and diabetes), large observational studies show that hypothyroidism is highly prevalent in kidney disease patients. For example, among 14 623 participants in the Third National Health and Nutritional Examination Survey (NHANES III), there was an incrementally higher prevalence of hypothyroidism (defined as TSH > 4.5 mIU/l or receipt of exogenous thyroid hormone supplementation) with increasing severity of kidney dysfunction: 5, 11, 20, 23, and 23% with estimated glomerular filtration rates (eGFRs) of greater than or equal to 90, 60-89, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] , and less than 30 ml/min/1.73 m 2 , respectively [3] . Even after accounting for differences in age, sex, and race/ethnicity, participants with eGFRs less than 30 ml/min/1.73 m 2 had a two-fold higher risk of hypothyroidism compared to those with eGFRs greater than or equal to 90 ml/min/1. 73 ]. Across these studies, a large proportion of cases have been due to subclinical hypothyroidism. In the aforementioned NHANES III study, 56% of hypothyroid cases were due to subclinical disease [3] . In a study of 3089 ambulatory adults in Italy, it was also found that there was an increasingly higher prevalence of subclinical hypothyroidism with lower levels of kidney function: 7 vs. 18% with eGFRs greater than or equal to 90 ml/min/1.73 m 2 vs. less than 60 ml/min/1.73 m 2 , respectively [11] .
A high prevalence of hypothyroidism has also been observed in dialysis patients, albeit in comparatively smaller sized cohorts. In the USA and Asian hemodialysis and peritoneal dialysis cohorts, the prevalence of hypothyroidism has ranged from 13 to 25% [9 & ,12-14] . Despite these data, hypothyroidism remains under-recognized in many advanced CKD patients, likely due to symptom overlap with uremia (e.g., fatigue, cold intolerance, and decreased cognition)
MECHANISTIC LINKS BETWEEN THYROID AND KIDNEY DISEASE
Thyroid functional disease as a risk factor for kidney disease Although the mechanistic link between thyroid and kidney disease remains unclear, animal studies have demonstrated that hypothyroidism adversely affects kidney size and structure in both development and adulthood ( Fig. 1) [15] . In neonatal rats,
KEY POINTS
CKD patients have a disproportionately higher prevalence of hypothyroidism, although many cases may remain latent and undiagnosed.
The thyroid-kidney mechanistic link has not been fully elucidated, but may be bidirectional.
Thyroid functional derangements, including hypothyroidism, are linked with cardiovascular disease and death in CKD patients.
Although limited data suggest benefit, future studies are needed to determine the safety and effectiveness of exogenous thyroid hormone replacement in hypothyroid CKD patients. hypothyroidism has resulted in reduced kidneyto-body weight ratio, truncated tubular mass, and various glomerular basement membrane (GBM) changes (e.g., reduced GBM volume and area, GBM thickening, mesangial matrix expansion, and increased glomerular capillary permeability) [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . It has also been suggested that hypothyroidism leads to kidney dysfunction, vis-à-vis several potential mechanisms, including decreased cardiac output, altered intrarenal hemodynamics (i.e., intrarenal vasoconstriction resulting from decreased vasodilator synthesis and activity), reduced reninangiotensin-aldosterone production and activity, and increased tubuloglomerular feedback due to alterations in chloride channel and expression [15, 23, [25] [26] [27] [28] . Indeed, in animal studies, induction of hypothyroidism by thyroidectomy has resulted in reduced single nephron glomerular filtration rate, renal plasma flow, and glomerular transcapillary pressure [29, 30] . Multiple case series have also shown that severe hypothyroidism results in creatinine elevations, reduced plasma flow, and decreased GFR as ascertained by indirect estimating equations and gold standard isotopic scans; in these reports, creatinine elevations and reductions in GFR were reversed with exogenous thyroid hormone replacement [31] [32] [33] . Some, but not all, epidemiologic studies have corroborated an association between hypothyroidism and kidney dysfunction. In a cross-sectional analysis of 461 607 US veterans who underwent repeated measures of serum TSH and creatinine testing at identical time points, each 10 ml/min/1.73 m 2 decrement in eGFR was associated with an 18% higher risk of hypothyroidism, independent of sociodemographics and comorbidities [10 & ]. In a prospective cohort study of 104 633 South Korean patients from the Kangbuk Samsung Health Study who had normal baseline kidney function and serum TSH levels and underwent annual to biennial TSH testing, those in the highest TSH quintile (2.85-5.00 mIU/l) had a 26% higher risk of incident CKD (defined as eGFR < 60 ml/min/1.73 m 2 using the CKD Epidemiology Collaboration formula) compared to those in the lowest TSH quintile (0.25-1.18 mIU/l) [34] . In analyses that examined TSH across a continuous spectrum using restricted cubic splines, higher TSH levels were associated with a progressively higher risk of CKD up to a TSH level of $3.20 mIU/l above which risk plateaued, suggesting that even high-normal TSH levels may be a risk factor for kidney dysfunction. However, the thyroid-dysfunction-CKD association has not been confirmed in all subpopulations. For example, in an analysis of 558 participants in the Leiden-85 study, a prospective follow-up study of 85-year-old inhabitants of Leiden, the Netherlands, cross-sectional analyses showed that those with overt and subclinical hypothyroidism (defined as TSH > 4.5 mIU/l with free T4 levels in the low or normal range, respectively) had lower mean AE SE eGFR levels than participants with normal kidney function: 53.7 AE 2.0, 55.7 AE 2.1, and 59.5 AE 0.7 ml/min/1.73 m 2 ; in contrast, participants with hyperthyroidism had the highest eGFR levels: 61.5 AE 3.1 ml/min/1.73 m 2 [35] . In addition, patients with higher TSH levels and lower free T4 levels had lower kidney function at baseline. However, in longitudinal analyses, there was no association between baseline thyroid functional status nor thyroid hormone concentrations with change in eGFR over a median follow-up of 5 years.
Limited data also suggest that, among patients with 'mild' subclinical hypothyroidism and CKD, thyroid hormone replacement may ameliorate kidney disease progression [36, 37] . Among 309 patients with subclinical hypothyroidism and Stages 2-4 CKD, compared with untreated patients (42%), those who were treated (58%) had a slower rate of eGFR decline (À2 vs. À6 ml/min/1.73 m 2 /year, respectively) and were less likely to experience a 50% decline in eGFR or end-stage renal disease [adjusted hazard ratio (95% confidence interval) 0.28 (0.12-0.68), respectively] [36] . In light of the sparse modifiable factors for CKD progression, further rigorous studies examining whether thyroid hormone replacement therapy modulates kidney function trajectory in hypothyroid CKD patients are needed.
Chronic kidney disease as a risk factor for thyroid dysfunction
Conversely, patients with CKD may be at higher risk for thyroid dysfunction via several suggested pathways ( Fig. 1 ). For example, iodine retention due to impaired kidney excretion has been hypothesized as a possible mechanism for hypothyroidism and hyperthyroidism in CKD via the Wolff-Chaikoff effect and Jod-Basedow phenomenon, respectively [38 & ]. Several case reports and series have reported iodine-associated hypothyroidism among adult and pediatric dialysis patients consuming high iodine diets (e.g., seaweed), exposure to povidine-iodine cleansing agents, and receipt of iodine-contrast media enhanced angiography [39] [40] [41] [42] . Although several recent observational studies have shown that iodinated contrast media is associated with higher risk of incident hypothyroidism and hyperthyroidism, a more potent association in those with vs. without kidney dysfunction has not been observed [43, 44 metabolic acidosis, which has been shown to result in thyroid functional test alterations [elevated TSH and low T4 and triiodothyronine (T3)] levels, partially improved with oral sodium citrate therapy [46, 47] . Selenium is an important trace mineral in the human diet that modulates the peripheral conversion of T4-to-T3 by controlling iodothyronine deiodinase activity [48] . However, in a double-blind randomized controlled trial of 64 hemodialysis patients with selenium deficiency who received oral selenium supplementation vs. placebo, there were no significant differences in TSH, T4, or T3 resin uptake levels after 3 months [49] . Lastly, given that the vast majority of circulating thyroid hormone is protein-bound, it has been suggested that heavy protein losses in nephrotic syndrome or via the dialysate in peritoneal dialysis patients may lead to total body thyroid hormone depletion [50, 51] .
THYROID FUNCTIONAL TEST ALTERATIONS IN CHRONIC KIDNEY DISEASE
Under normal circumstances, thyroid hormone synthesis is under the regulation of the hypothalamic-pituitary-thyroid axis. Thyrotropin-releasing hormone (TRH) produced by the hypothalamus incites the release of TSH from the anterior pituitary, which in turn stimulates the synthesis and secretion of T4, and to a lesser degree T3, by the thyroid gland [15] . Although T4 is generated in the thyroid gland, 80% of T3 is produced by the peripheral conversion of T4-to-T3 by type 1 and 2 5 0 -deiodinase enzymes. In a multiloop feedback system, T4 and T3 exert negative feedback inhibition of TRH and TSH.
CKD patients may experience alterations in regulation of the hypothalamic-pituitary-thyroid axis. In addition, as the kidney is involved in the metabolism, degradation, and excretion of certain thyroid hormones and their metabolites, various thyroid functional test alterations may occur in
Thyrotropin
In the general population, serum TSH is typically used for screening, diagnosis, and treatment monitoring and titration in primary hypothyroidism [2] . In CKD, certain TSH alterations may be observed, such as impaired clearance, protracted half-life, blunted pulsatility, altered glycosylation leading to impaired bioactivity, and decreased response to TRH [4, 52] . Given its inverse logarithmic association with serum T3 and T4 levels (i.e., small changes in T3 and T4 induce exponential changes in TSH), it is regarded as the most sensitive and specific single biochemical measure of thyroid function. In addition, serum TSH is a more robust thyroid function metric in nonthyroidal illness [2] . Although low T3 and T4 levels are typically observed with mild-to-moderate illness, TSH typically remains normal until the onset of severe, critical illness [48, 53] .
Triiodothyronine and reverse triiodothyronine
Limited data indicate that low T3 levels are the most commonly observed thyroid functional test alteration in CKD patients. For example, in a study of 2284 CKD patients who had normal TSH levels, there was an incrementally higher prevalence of low T3 with increasingly impaired kidney function, such that over three-quarters of patients with Stage 5 CKD had low levels: 8, 11, 21, 60, and 79% with eGFRs greater than or equal to 90, 60-89, 30-59, 15-29, and less than 15 ml/min/1.73 m 2 [54] . As the aforementioned peripheral deiodination of T4-to-T3 is reduced by malnutrition, inflammation, nonthyroidal illness, certain medications, and in the presence of high serum cortisol and free nonesterified fatty acid levels, it has been suggested that low T3 levels are a marker of illness in CKD patients [10 & ,48,53]. Reverse T3 is a metabolically inactive form of thyroid hormone that is produced from its precursor, T4, by the type 3 5 0 -deiodinase enzyme [55, 56] . This enzyme also degrades reverse T3 into inactive diiodothyronine. In nonthyroidal illness, reverse T3 levels are typically high due to heightened production and reduced decomposition [4, 56] . In hypothyroidism, reduced production of T4 typically results in low reverse T3 concentrations, although levels may be normal or high in mild hypothyroidism. Although reverse T3 is oftentimes normal in kidney dysfunction, the clinical significance of these levels in the interpretation of thyroid functional tests in CKD remains undefined [1 & ].
Total and free thyroxine
Given that the vast majority of circulating T4 is bound to proteins, including thyroid-binding globulin, transthyretin, albumin, and lipoproteins, total T4 levels (capturing both free and protein-bound hormone) may be spuriously low in low-protein states [57] . Although free T4 levels are used to ascertain the proportion of biologically active, nonprotein-bound hormone, routinely used free T4 assays (e.g., analog method) are dependent upon proteinhormone binding, and hence may not be accurate in abnormal protein states (e.g., hypoalbuminemia and pregnancy) or in the presence of certain medications (e.g., furosemide and heparin) or substances that impair protein-hormone binding (e.g., uremic toxins) [56, 57] . To overcome this limitation, direct free T4 assays separate free and protein-bound T4 using equilibrium dialysis or ultrafiltration, and use liquid chromatography tandem mass spectrometry or radioimmunoassay to measure free T4 [57] [58] [59] . Although direct free T4 levels have shown stronger inverse correlations with the log of TSH compared with indirect FT4 in populations with normal and altered protein-hormone binding (e.g., pregnancy) [60] [61] [62] , further studies are needed to determine their utility in the classification of thyroid function and prognostication of outcomes in CKD.
THYROID FUNCTIONAL DISEASE AND OUTCOMES IN CHRONIC KIDNEY DISEASE

Cardiovascular disease
In general population, hypothyroidism has been associated with various adverse cardiovascular outcomes (Table 1) [63] . Given that end-stage renal disease patients have a seven-fold to 10-fold higher mortality risk (40% of deaths due to cardiovascular causes) compared with the general population [64, 65] , there has been increasing interest in hypothyroidism as an under-recognized cardiovascular risk factor in advanced CKD [1 & ]. To date, most studies of thyroid function and cardiovascular endpoints in this population have focused upon low T3 as the thyroid functional test metric, which has been associated with endothelial dysfunction, atherosclerosis, vascular calcification, impaired systolic function, increased left ventricular mass, and abnormal ventricular conduction [66, 67, 68 && , [69] [70] [71] [72] . There have been comparatively fewer studies of thyroid function ascertained by TSH and cardiovascular outcomes in CKD. In a cross-sectional study of 51 ambulatory peritoneal dialysis patients, subclinical hypothyroidism (defined as TSH > 5 mIU/l and normal free T4) was associated with impaired left ventricular function [7] . In a recent study of 97 end-stage renal disease patients selected to undergo living donor kidney transplantation, low TSH, free T3, and free T4 levels (interpreted as markers of nonthyroidal illness) were inversely associated with higher coronary artery calcification scores [68 && ].
Mortality
In the general population, studies of hypothyroidism (largely focused upon subclinical disease) and mortality have been mixed [73] . However, a metaanalysis of 55 287 patients across 11 cohort studies conducted by the Thyroid Studies Collaboration showed that patients with subclinical hypothyroidism and TSH levels greater than 7 mIU/l had a higher risk of coronary heart disease death [74] . It has also been suggested that the hypothyroidism-mortality association may be dependent upon underlying cardiovascular risk. Indeed, in a study of 14 879 NHANES III participants, both hypothyroidism overall and subclinical hypothyroidism were associated with higher mortality in participants with heart failure, but not in those without heart failure [13] . These findings may bear analogy to advanced CKD patients given their high prevalence of structural heart disease [64] . Early studies of thyroid function in CKD suggested that thyroid hormone deficiency is a physiologic adaptation and a means to conserve metabolism in end-stage renal disease patients who are hypercatabolic and prone to protein-energy wasting and dialytic protein and amino acid losses [5] . However, contemporary studies demonstrating an association between hypothyroidism and higher death risk in dialysis patients have challenged this hypothesis. In the first study to examine thyroid function defined by TSH and mortality, among 2715 incident and prevalent dialysis patients it was found that hypothyroidism ascertained at study entry (defined as TSH > assay reference upper limit of normal) was associated with a 35% higher all-cause mortality risk compared with euthyroidism [8] . Yet in a study of 1000 incident and prevalent diabetic hemodialysis patients from the Deutsche Diabetes Dialyse Studie, baseline subclinical hypothyroidism examined separately or in conjunction with overt hypothyroidism was not associated with sudden cardiac death, cardiovascular events, or all-cause death; notably, only 1.8% of the study cohort had subclinical hypothyroidism (defined as TSH 4.1-15.0 mIU/l with normal free T3 and T4 levels) or overt hypothyroidism (defined as TSH > 10.0 IU/l and low free T3 and/or free T4 levels), which may have resulted in limited power to detect significant associations [6] . In a subsequent study of 8840 hemodialysis patients from a large national dialysis organization that examined baseline and repeated measures of TSH over time, it was found that baseline and time-dependent hypothyroidism (defined as TSH > 5.0 mIU/l) were associated with a 47 and 62% higher all-cause death risk compared with euthyroidism, respectively [9 & ]. Upon examination of finer gradations of TSH, it was found that higher levels were incrementally associated with higher death risk, such that even high-normal TSH ranges (>3.0-5.0 mIU/l) predicted heightened mortality risk. To explore the hypothesis that hypothyroidism is a physiologic adaptation in advanced CKD patients prone to protein-energy wasting, thyroid function-mortality associations were examined across strata of BMI. Notably, time-dependent analyses showed stronger associations across higher BMI categories, whereas baseline analyses showed that the hypothyroidism-mortality association was abrogated in those with a BMI 20 kg/m 2 or less. In summarizing these collective observational studies, various conclusions may be drawn regarding the association of hypothyroidism and death in CKD (Fig. 2 ).
MANAGEMENT OF HYPOTHYROIDISM IN CHRONIC KIDNEY DISEASE
Future studies examining the impact of exogenous thyroid hormone treatment upon cardiovascular disease and death may yield key insights into the causal implications of hypothyroidism in CKD. Indeed, the United States Renal Data System Annual Data Report has shown that levothyroxine is among the most commonly prescribed medications in nondialysis-dependent CKD and end-stage renal disease who are Medicare Part D enrollees [65] . However, there has been a paucity of data examining exogenous thyroid hormone replacement in hypothyroid CKD patients. As noted above, observational studies have shown that receipt of exogenous thyroid hormone replacement in patients with subclinical hypothyroidism and CKD was associated with decreased CKD progression [36, 37, 65] . Similarly, in a double-blinded randomized controlled trial of 136 patients with subclinical hypothyroidism (defined as TSH of 4.0-7.0 mIU/l and serum thyroid peroxidase antibody positivity) and early type 2 diabetic nephropathy, treatment with levothyroxine for 48 experienced adverse cardiovascular reactions including mild paroxysmal supraventricular tachycardia (n ¼ 1) and palpitations (n ¼ 5). To date, there has been one study that has examined exogenous thyroid hormone replacement and mortality in hypothyroid CKD patients. Among 2715 dialysis patients whose thyroid function and treatment status were ascertained at baseline, those who were euthyroid on treatment (presumed to be 'hypothyroid-treated-to-target') had a similar mortality risk compared with those who were spontaneously euthyroid, whereas patients who were hypothyroid irrespective of treatment status had higher mortality risk [8] .
Although these limited data suggest benefit, levothyroxine bears a narrow toxic-to-therapeutic window [76] , and iatrogenic thyrotoxicosis and/or unwarranted treatment may theoretically lead to complications such as increased protein catabolism, reduced bone mineral density, and arrhythmia, particularly in advanced CKD patients with high underlying cardiovascular risk [1 & ,5,77 & ]. Thus, at this time, rigorous longitudinal studies and future randomized controlled trials with larger sample sizes and extended follow-up periods will provide more definitive information on the safety and effectiveness of exogenous thyroid hormone supplementation in hypothyroid CKD patients.
CONCLUSION
There are many remaining gaps in knowledge with regard to the interaction between thyroid and kidney disease. Further mechanistic studies are needed to understand the pathogenesis of thyroid functional disorders in kidney disease, as well as how CKD may engender thyroid dysfunction. Future research is also needed to identify more sensitive and specific methods of classifying thyroid functional status in CKD patients to more accurately distinguish true thyroid functional disease from nonthyroidal illness in this population. Given that thyroid hormone receptors are present in nearly all tissues, hypothyroidism may have pervasive effects on multiple end organs (e.g., neuropsychiatric, hematologic, and musculoskeletal); thus, further studies are needed to determine the underlying mechanistic pathways by which hypothyroidism is linked with mortality. Lastly, rigorous studies of the impact of exogenous thyroid treatment, including dosing and biochemical targets, upon kidney disease progression, cardiovascular disease, and mortality, are needed to better understand the causal implications of hypothyroidism in CKD patients.
